• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Philip Morris International Presents its Value Report 2025: change in motion

    3/31/26 4:30:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email

    The company's annual disclosure unveils its Value Plan 2030+

    Philip Morris International (NYSE:PM) today released its Value Report 2025, offering a holistic perspective on the company's approach to sustainable value creation. The report marks the completion of PMI's 2025 Roadmap, communicating achievements for each aspiration introduced by the company in 2020, and introduces its Value Plan 2030+, set to guide the company's continued path to sustainable growth.

    "For more than a decade, PMI has pursued an industry-leading shift away from cigarettes—a transformation that goes far beyond product innovation to encompass how we allocate capital, engage stakeholders, and measure success," said Jacek Olczak, Group Chief Executive Officer. "‘change in motion' captures the reality that transformation is not a project with a defined end date, it is the continuous work of improvement, innovation, and adaptation that keeps us relevant and resilient. We transform continuously because markets evolve, science advances, stakeholder expectations rise, and new opportunities emerge. This is who we are: a company perpetually in motion toward a better future, refusing to stand still even as we celebrate how far we have come."

    Built on the progress that PMI has made over the past decade, the report explains how the company is securing the resources, capabilities, and stakeholder trust that will sustain its business for decades to come. The sustainability of the business is PMI's strategy; it is how it secures resources, manages risk, meets stakeholder expectations, and future-proofs a business built to deliver results today, while securing the ability to deliver tomorrow.

    "Our approach to value creation is anchored in a simple conviction: long-term financial success depends on the health of the resources and relationships that make it possible. By investing in natural, human, social, intellectual, and manufactured capital—what we define as non-financial capitals—we strengthen the very foundations on which long-term financial success depends," said Emmanuel Babeau, Group Chief Financial Officer. "This is fundamental to our growth, resilience, and identity as a forward-thinking organization."

    PMI achieved meaningful progress across both product and operational impact in 2025, as it closed its 2025 Roadmap.

    PMI's Business Transformation Metrics (BTMs) have provided stakeholders with clear, comparable indicators of our progress toward a smoke-free future. These metrics go beyond traditional reporting frameworks to capture aspects unique to PMI's change of motion. They include the following:

    • Around 43.5 million adult consumers of smoke-free products worldwide.i
    • PMI's smoke-free products were available for sale in 106 markets.ii
    • PMI's smoke-free business net revenues reached USD 16.9 billion and represented 41.5% of total annual net revenues.iii

    In addition, PMI celebrated progress on:

    • 98% coverage of shipment volume with youth access prevention programs in its indirect retail channels.iv
    • 91% coverage of shipment volumes with PMI's anti-littering programs for cigarette butts.v
    • 76% of PMI employees globally had access to structured lifelong learning opportunities. vi
    • 99.6% of contracted farmers supplying tobacco to PMI made a living income by year-end 2025. This was achieved through initiatives aimed at boosting farm productivity and encouraging income diversification.vii
    • 99.3% of tobacco purchased at no risk of net deforestation of managed natural forest and no conversion of natural ecosystems.viii
    • 46% decrease versus 2019 on absolute Scope 1 and 2 greenhouse gas (GHG) emissions, with the company achieving carbon neutrality in its direct operationsix, and PMI's absolute Scope 3 Forest, Land, and Agriculture (FLAG) GHG emissions decreased by 31% versus 2010.x

    "We have identified six strategic priorities that reflect what matters most to our stakeholders and our business: consumers and product health impact, circularity, climate change, nature and biodiversity, our own workforce, and workers throughout our value chain, which are consolidated in our Value Plan 2030+. This plan identifies where our actions intersect most significantly with business imperatives, ensuring our initiatives drive tangible outcomes across various forms of capital, creating a strategy that is comprehensive yet focused, ambitious yet pragmatic, and deeply integrated into how we operate and grow," said Jennifer Motles, Chief Sustainability Officer. "Our plan is explicit about what we control directly and what requires the action of, and partnership with others, setting a strong foundation for effective action. That is the spirit with which we present our Value Plan 2030+, as an invitation to dialogue, a platform for collaboration, and a roadmap for the next chapter: turning sustainability into lasting business value."

    PMI's Value Plan 2030+ sets the course for the company's next chapter—a continuation of the change in motion that has defined PMI's evolution over the past decade. It focuses on accelerating the growth of its smoke-free product portfolio, working to make cigarettes obsolete, and exploring adjacent avenues of growth in wellness, while maintaining responsible sales and marketing practices, investing in human and natural capital, and strengthening the operational resilience that underpins long-term, sustainable value creation.

    PMI's Value Report 2025 has been prepared with reference to the Global Reporting Initiative (GRI) Universal Standards (2021) and relevant topic-specific standards. This report follows guidance from the International Sustainability Standards Board (ISSB) of the IFRS Foundation, including SASB Standards, Integrated Thinking Principles, and the Integrated Reporting Framework. Beginning with the 2025 reporting cycle, the company renamed its annual disclosure from the ‘Integrated Report' to the ‘Value Report' to reflect its commitment to transparency, communicating how it creates, preserves, and enhances value over the short, medium, and long term. The Value Report continues to build on the foundation established by previous Integrated Reports, providing a comprehensive and integrated view of PMI's strategy, management, performance, and outlook in relation to its most significant sustainability-related topics.

    Please visit www.pmi.com/sustainability to learn more and read the full 2025 Value Report, as well as Stories of Impact.

    Philip Morris International: A Global Smoke-Free Champion

    Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. Our smoke-free products are available for sale in over 105 markets, and as of December 31, 2025, PMI estimates they were used by over 43 million legal-age consumers around the world, many of whom have moved away from cigarettes or significantly reduced their consumption. The smoke-free business accounted for 41.5% of PMI's full year 2025 total net revenues. Since 2008, PMI has invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness areas. References to "PMI", "we", "our" and "us" mean Philip Morris International Inc., and its subsidiaries. For more information, please visit www.pmi.com and www.pmiscience.com.

    Forward-Looking and Cautionary Statements

    This press release contains projections of future results and goals and other forward-looking statements, including statements regarding business plans and strategies. Achievement of future results is subject to risks, uncertainties, and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI.

    PMI's business risks include: marketing and regulatory restrictions that could reduce our competitiveness, disrupt our SFP commercialization efforts, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; excise tax increases and discriminatory tax structures; health concerns relating to the use of tobacco and other nicotine-containing products; litigation related to tobacco and/or nicotine products and intellectual property rights; intense competition; inability to anticipate changes in adult consumer preferences; use and reliance on third-parties; the adverse effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; geopolitical instability affecting international trade; the impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; continued decline of tax-paid cigarettes; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, sustained periods of elevated inflation, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; disruptions in the credit markets or changes to its credit ratings; recent and potential future tariffs imposed by the U.S. and other countries; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as product components for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful, in key markets or systemically, in its efforts to introduce, commercialize, and grow smoke-free products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity; if there are prolonged disruptions of facilities used to produce its products; if it is unable to enter new markets or improve its margins through increased prices and productivity gains; if other market participants are more successful in their SFP commercialization efforts; if it is unable to attract and retain the best global talent; or if it is unable to successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results are also subject to the lower predictability of our smoke-free products performance.

    PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2025. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.

    ________________________________

    i Total PMI smoke-free users is defined as the sum of total IQOS users, total oral smokeless users, and total e-vapor users of PMI products and considering poly-users across PMI's smoke-free product categories. For definitions, see Glossary in PMI's Value Report 2025.

    ii For definition of available for sale, see Glossary in PMI's Value Report 2025.

    iii For definition of net revenues related to smoke-free, see Glossary in PMI's Value Report 2025. This information should be read in conjunction with the Reconciliation of non-GAAP measures in PMI's Value Report 2025.

    iv Total shipment volume includes cigarettes, other tobacco products (OTPs), and smoke-free product consumables. See PMI's Non-financial KPI hub for further details.

    v See PMI's Non-financial KPI hub for further details.

    vi See PMI's Non-financial KPI hub for further details.

    vii Excludes China, Thailand, Switzerland, and India (flue-cured). See PMI's Non-financial KPI hub for further details on methodology.

    viii For definitions, please see PMI's Zero Deforestation Manifesto and PMI's Non-financial KPI hub.

    ix Ambition achieved in early 2026 against 2025 emissions; data refer to yearly gross emissions from the reporting year minus the retroactive offsetting of the previous year's emission. See PMI's Non-financial KPI hub for further details.

    x For further details on scope 3 calculation, please refer to PMI's Value Chain Carbon Footprint Methodology Overview and PMI's Non-financial KPI hub.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260331272710/en/

    Corey Henry

    Philip Morris International

    T. +1 (202) 679 7296

    E. [email protected]

    Get the next $PM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    1/20/2026$180.00Buy → Hold
    Jefferies
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    More analyst ratings

    $PM
    SEC Filings

    View All

    SEC Form DEFA14A filed by Philip Morris International Inc

    DEFA14A - Philip Morris International Inc. (0001413329) (Filer)

    3/31/26 2:03:06 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Philip Morris International Inc

    SCHEDULE 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    3/27/26 11:22:44 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEFA14A filed by Philip Morris International Inc

    DEFA14A - Philip Morris International Inc. (0001413329) (Filer)

    3/26/26 6:06:32 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Philip Morris International downgraded by Jefferies with a new price target

    Jefferies downgraded Philip Morris International from Buy to Hold and set a new price target of $180.00

    1/20/26 9:10:49 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Needham initiated coverage on Philip Morris International with a new price target

    Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

    5/22/25 8:27:06 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Philip Morris International Presents its Value Report 2025: change in motion

    The company's annual disclosure unveils its Value Plan 2030+ Philip Morris International (NYSE:PM) today released its Value Report 2025, offering a holistic perspective on the company's approach to sustainable value creation. The report marks the completion of PMI's 2025 Roadmap, communicating achievements for each aspiration introduced by the company in 2020, and introduces its Value Plan 2030+, set to guide the company's continued path to sustainable growth. "For more than a decade, PMI has pursued an industry-leading shift away from cigarettes—a transformation that goes far beyond product innovation to encompass how we allocate capital, engage stakeholders, and measure success," said

    3/31/26 4:30:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    PMI U.S. BRINGS TECHNOVATION TO WASHINGTON D.C.

    PMI's global science and innovation platform brings together leaders to accelerate progress toward a smoke-free futureWASHINGTON, March 30, 2026 /PRNewswire/ -- Technovation, the global science and innovation platform of Philip Morris International (PMI) (NYSE:PM), will make its U.S. debut on April 14. The one-day event brings together experts, policymakers, scientists, media, and business leaders across the Americas to explore how innovation, science, and regulation can accelerate progress toward a smoke-free future. The U.S. launch of Technovation marks a key moment for the pl

    3/30/26 8:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Declares Regular Quarterly Dividend of $1.47 Per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.47 per common share, payable on April 13, 2026, to shareholders of record as of March 19, 2026. The ex-dividend date is March 19, 2026. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily

    3/5/26 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Group Controller Dobrowolski Reginaldo covered exercise/tax liability with 22 shares (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    3/9/26 4:23:03 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Group Chief Financial Officer Babeau Emmanuel covered exercise/tax liability with 2,228 shares and sold $6,138,418 worth of shares (33,800 units at $181.61), decreasing direct ownership by 18% to 164,463 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    2/20/26 4:01:45 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Group Controller Dobrowolski Reginaldo covered exercise/tax liability with 250 shares and sold $1,100,880 worth of shares (6,000 units at $183.48), decreasing direct ownership by 20% to 21,182 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    2/20/26 4:01:38 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    View All

    Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI

    The paper calls for global debate to ensure AI enhances—rather than diminishes—uniquely human strengths in an increasingly automated world Philip Morris International Inc. (NYSE:PM) today released a new white paper, "Human Cognition: The Next Frontier?", inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the "superskill" of the future, driving progress in an era of human-machine collaboration. As AI automates routine ta

    1/20/26 5:03:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    9/17/24 9:11:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Names New External Affairs Leader

    Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

    3/26/24 5:48:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:21:26 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:05:54 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    1/29/24 3:26:29 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Financials

    Live finance-specific insights

    View All

    Philip Morris International Declares Regular Quarterly Dividend of $1.47 Per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.47 per common share, payable on April 13, 2026, to shareholders of record as of March 19, 2026. The ex-dividend date is March 19, 2026. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily

    3/5/26 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Presents at 2026 CAGNY Conference; Reaffirms 2026 Full-Year Forecast

    Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Group CEO PMI, Jacek Olczak, and Group Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2026 Consumer Analyst Group of New York (CAGNY) Conference at approximately 10:00 a.m. ET. The live webcast and presentation slides will be available here. The webcast replay will be available at the same link for six months after the event. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The presentation will cover: How a transformed PMI is leading the industry in an evolving operating environment; The success and future opportu

    2/18/26 7:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Reports 2025 Fourth-Quarter & Full-Year Results

    Delivers Full Year 2025 Reported Diluted EPS of $7.26 compared to $4.52 in 2024 and Adjusted Diluted EPS of $7.54, Representing Growth of 14.8%, and 14.2% on a Currency-Neutral Basis; Provides 2026 - 2028 Growth Targets Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 fourth quarter results.1 "We achieved another remarkable year of results in 2025, with a fifth consecutive year of volume growth, net revenues surpassing $40 billion, including close to $17 billion from our smoke-free business, and very good operating margin expansion," said Jacek Olczak, Group CEO PMI. "With excellent results in 2024 and 2025, we have delivered our three-year CA

    2/6/26 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care